Abstract
The incidence of human papillomavirus-positive oropharyngeal cancer (HPV/OPSCC) is rapidly increasing, which will represent a major public health burden for decades to come. Although HPV/OPSCC is generally associated with a better prognosis than HPV-negative OPSCC, the survival rate of individuals with higher-risk clinical and pathologic features remains unchanged. Emerging evidence suggests that HPV/OPSCC is pathologically and molecularly distinct from HPV-negative OPSCC. This review focuses on summarizing treatment strategies for HPV/OPSCC by reviewing the peer-reviewed literature and noting ongoing and planned clinical trials in this disease. We also discuss the potential of designing targeted therapy based on the recent genomic findings of HPV/OPSCC.
Original language | English (US) |
---|---|
Pages (from-to) | 91-97 |
Number of pages | 7 |
Journal | Head and Neck Pathology |
Volume | 6 |
Issue number | SUPPL. 1 |
DOIs | |
State | Published - 2012 |
Externally published | Yes |
Keywords
- Chemotherapy
- HPV/OPSCC
- Radiation
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Otorhinolaryngology
- Oncology